Company
Atossa Therapeutics Inc
NASDAQ:ATOS
Seattle-based Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology. The company's current focus is on breast cancer.
50 stories
Atossa Genetics pops after receiving $10M from exercise of outstanding warrants
The warrants were issued by the Seattle biopharma in its rights offering completed last May
Atossa Genetics soars after FDA approves drug Endoxifen for single breast cancer patient
The use of Atossa’s oral Endoxifen, a metabolite of tamoxifen, is restricted to one patient
Atossa Genetics kicks off Phase 2 study of topical Endoxifen to reduce breast density
Studies show that a reduction in breast density reduces the risk of developing breast cancer
Atossa Genetics shares swell as dosing phase of its topical drug to treat male breast enlargement ends
Analysts at Maxim Group said catalysts from an expected data readout in 3Q could drive valuations higher
Atossa Genetics poised to execute clinical programs that may unlock shareholder value, says Maxim Group
The Seattle-based drug company is developing both oral and a topical formulation of its flagship breast cancer candidate endoxifen
Atossa given green light to begin mid-stage trial of flagship breast cancer drug
Endoxifen is the most active ingredient in tamoxifen, which has been used to prevent recurrence in beast cancer survivors for more than 40 years